Immunomic Therapeutics Expands Board of Directors
Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced that it has appointed Steve Sang Yong Park and Robert V. Ahlgren as new members to its Board of Directors, expanding the board to twelve members.
- Steve Sang Yong Park most recently served as Senior Managing Director and Chairman of Korea Equity Capital Solutions for Macquarie Group located in Seoul, Korea, a position he held until June 2021. In his role, he was responsible for equity capital markets activities for Macquarie Group in Korea.
- Robert V. Ahlgren brings over 30 years of management and leadership experience in the scientific laboratory supply and diagnostic manufacturing industries to ITI. Most recently, he served as Group President Global Distribution for a division of Fisher Scientific from 2004 until 2006, when he retired.
Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical-stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that have the potential to generate broad immune responses.